Xolair Market Report 2026

Xolair Market Overview

• The Xolair market growth in the historic period has been driven by increasing prevalence of asthma and allergic disorders, expansion of biologic drug approvals • Market expansion is supported by increasing demand for personalized allergy treatments, expansion of biologics into additional inflammatory indications • Growth Driver: Impact Of Rising Asthma Prevalence On The Growth Of The Market • Market Trend: Focus On IgE-Mediated Conditions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Xolair Market?

Xolair (omalizumab) is a monoclonal antibody medication used to treat moderate to severe asthma, chronic idiopathic urticaria (hives), and nasal polyps. It works by targeting and inhibiting immunoglobulin E (IgE), a key antibody involved in allergic reactions, thereby reducing inflammation and improving symptom control. Xolair is typically prescribed for patients whose conditions are inadequately controlled with standard therapies. The main types of indications in xolair include asthma, chronic spontaneous urticaria (CSU), and nasal polyposis. The asthma segment involves using omalizumab to manage moderate to severe allergic asthma by reducing airway inflammation and preventing attacks in patients unresponsive to standard treatments. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies for end users such as adults, geriatrics, and pediatrics.

What Is The Xolair Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for personalized allergy treatments, expansion of biologics into additional inflammatory indications, rising investments in immunology research, growing adoption of long-acting injectable therapies, improved access to specialty biologic drugs. Major trends in the forecast period include increasing adoption of targeted monoclonal antibody therapies, rising demand for biologic treatments in chronic allergic conditions, expansion of long-term disease management approaches, growing focus on precision immunology treatments, enhanced emphasis on patient-centric biologic care.

Global Xolair Market Segmentation

1) By Indication: Asthma, Chronic Spontaneous Urticaria (CSU), Nasal Polyposis 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Adults, Geriatric, Pediatric

What Is The Driver Of The Xolair Market?

An increase in the prevalence of asthma is expected to propel the growth of the xolair market going forward. Asthma is a chronic condition where the airways become inflamed and narrowed, causing difficulty in breathing, wheezing, and coughing. The increasing prevalence of asthma and allergic conditions can be attributed to increased exposure to pollutants, rising temperatures, changing weather patterns, and higher population density. Xolair effectively treats asthma by targeting IgE antibodies, reducing airway inflammation, and preventing asthma attacks in patients with moderate to severe allergic asthma. For instance, in December 2024, according to data from the National Center for Health Statistics (NCHS), a U.S.-based health statistics agency, the prevalence of current asthma among adults aged 18 and over in the United States increased from 3.7% in 2022 to 3.8% in 2023. Thus, an increase in the prevalence of asthma is driving the growth of the xolair industry.

Key Players In The Global Xolair Market

Major companies operating in the xolair market are F. Hoffmann-La Roche AG, Novartis AG

Global Xolair Market Trends and Insights

The key trend in the xolair market is focused on the expansion of approved indications for existing drugs, particularly in the area of allergy and immunology treatments such as Omalizumab, to broaden market reach and address unmet medical needs in niche and high-demand areas. IgE-mediated food allergies are immune responses triggered by immunoglobulin E (IgE) antibodies, causing rapid allergic reactions upon exposure to specific food allergens. For instance, in February 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, received FDA approval for Xolair (omalizumab) to reduce allergic reactions, including anaphylaxis, in patients aged 1 and older with IgE-mediated food allergies. Xolair is the first FDA-approved treatment for reducing allergic reactions to multiple food allergens but is not intended for emergency use. Patients should continue avoiding allergens. The treatment is now available for eligible patients in the U.S.

What Are Latest Mergers And Acquisitions In The Xolair Market?

In October 2023, Alvotech, a Luxembourg-based biotechnology company, entered into a licensing agreement with Kashiv Biosciences to develop AVT23, a biosimilar to Xolair (omalizumab), which is marketed by Roche and Novartis. The collaboration aims to develop AVT23 as a biosimilar to Xolair, which is used primarily for the treatment of allergic asthma and chronic spontaneous urticaria. Kashiv Biosciences is a US-based biopharmaceutical company engaged in the manufacturing of Xolair biosimilars.

Regional Insights

North America was the largest region in the xolair market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Xolair Market?

The xolair market consists of sales of subcutaneous injections with 150 mg/1.2 mL prefilled syringes and 75 mg/0.5 mL prefilled syringes. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Xolair Market Report 2026?

The xolair market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the xolair industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.